Geron Discontinues Phase 3 Myelofibrosis Trial
Geron announced a decision to discontinue the Phase 3 IMpactMF trial evaluating imetelstat in relapsed/refractory myelofibrosis.
Story updates
12:04:49 PM UTC
SquawkNews
Geron will discontinue the Phase 3 IMpactMF trial of imetelstat in JAK inhibitor relapsed/refractory myelofibrosis after the DMC said it was unlikely to meet overall survival. No new safety signals were observed. Geron plans a detailed data analysis and future disclosure.Material DetailsContext by…
12:12:19 PM UTC
SquawkNews
Geron halts Phase 3 imetelstat myelofibrosis trial as survival goal appears unlikely Geron will
FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation NASDAQ:GERN, a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor relapsed/refractory myelofibrosis. This decisi…